This previous process, which prioritised the need to secure broad industry support for reforms, has been displaced by a system of layered privilege. This is partly due to the government's more aggressive and impatient approaches to reform and partly because the industry has become more acquiescent.
These layered levels of privilege are not making decision-making or the system better
July 25, 2024 Latest NewsBioPharma
Latest Video
New Stories
-
Medicines Australia announces appointment of communications director
April 28, 2025 - - Latest News -
New survey confirms significant interest in accessing weight loss therapies
April 28, 2025 - - Latest News -
Recce Pharmaceuticals enters research and development agreement with US defence
April 28, 2025 - - Australian Biotech -
Radiopharm Theranostics doses first patient in US Phase 2b imaging study of brain metastasis
April 28, 2025 - - Australian Biotech -
Dimerix says FDA confirms proteinuria as acceptable endpoint for DMX-200 Phase 3 trial
April 28, 2025 - - Australian Biotech -
Stakeholders welcome the PBS listing of AbbVie's blood cancer therapy
April 28, 2025 - - Latest News -
Repurposed diabetes drug could deliver gains for people living with major joint pain
April 27, 2025 - - Latest News